Clinical trial · Observational
Quality of Life in Lymphoma Patients One Year Post-chemotherapy
Quality of Life in Lymphoma Patients and Cancer Care Pathway One Year Post-chemotherapy
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Malignant lymphomas are considered as among the most chemo-sensitive cancers. ML are cured in more than 85% of patient, the majority with complete response. After this active phase of treatment, patients are in "after cancer period". Toulouse University Hospital developed since 2006 the Ambulatory Medical Assistance for After Cancer program on lymphoma patient. Ambulatory Medical Assistance for After Cancer is very efficient for detecting physical and psychological complications which impact quality of life. The investigators identified 22% of lymphoma patients who had a reduced quality of life one year after the end of chemotherapy. The present study aims to investigate the evolution of observed complications and identify cancer care pathway which decrease the quality of life reduction risk in patients one year after lymphoma chemotherapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lymphoma | Lymphoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Quality of life | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Lymphoma patients
- description
- Patients being in complete response after a first therapy for malignant lymphoma.
- interventionNames
- Other: Quality of life
Primary outcomes (1)
- measure
- Quality of life change: Quality of Life-C30 French version
- timeFrame
- Change from baseline quality of life at 12 month
- description
- Health-related quality of life is evaluated by the use of Quality of Life-C30 French version
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients being in complete response after a first therapy for lymphoma * Malignant lymphoma (Hodgkin or non-Hodgkin) treated by anthracyclines with a minimum of 6 cycles, followed or not by autologous hematopoietic stem cell transplantation * Patients informed of the study and not opposed to the research Exclusion Criteria: * Patients under legal guardian . * Patients unavailable to formulate non-opposition to the study
References
Publications (0)
Data not yet available